spacer
home > ict > autumn 2020 > modernisation movement
PUBLICATIONS
International Clinical Trials

Modernisation Movement

EPC: Has the process of modernising site operations slowed due to the pandemic?

Anna Argyris: COVID-19 halted a large number of trials. This slowed research, but actually accelerated modernisation efforts in site operations. As sites are now navigating new ways of working, technology has played an important role in allowing sites to reopen safely.

We're hearing from multiple sites that COVID-19 has been a catalysing event for them, especially those that did not previously have technology solutions in place. In some cases, the pandemic has given sites the business justification they needed to be able to accelerate their modernisation efforts. At the same time, sites have focused on reducing the burden on patients participating in clinical trials. Patients take a significant amount of time out of their lives to participate in research. For some patients, the burden of a trial can become too great and they may need to withdraw from a study or not complete important follow-up study visits. The future of clinical studies lies with helping sites and patients eliminate some of those burdens through technology.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Anna Argyris, Director of Site Solutions at Veeva Systems, has over 10 years of clinical research leadership experience and has worked at Mayo Clinic, Georgetown University, Houston Methodist, and UCSF. She led several technical projects involving CTMS, EHR, eTMF, and eRegulatory systems. Her research expertise includes study feasibility and logistics planning, finance and forecasting, programme development, coverage analysis, billing compliance, and business process design. Anna currently supports the strategy for Veeva’s research site solutions.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement